4
NEWS
Dedicated NHS Diabetes Advice helpline
0345 123 2399
Dexcom ONE+ sensor
launched
Dexcom has announced that it has launched the Dexcom ONE+ continuous
glucose monitor (CGM) in the UK.
Dexcom ONE+ uses Dexcom's established sensor design, with the
company incorporating feedback from users and healthcare professionals
to build it. The company says this ensured an easy-to-use, highly effective
CGM experience for people treating Type 1 or Type 2 diabetes with insulin.
This version of the platform utilizes the latest-generation G7 sensor,
while the previous version used the G6. The Dexcom ONE+ monitor also
adds certain notes at certain moments, like meals, insulin administration
and sports activities.
Dexcom began rolling out the system in Spain, Belgium and Poland in
February. It followed that up with rollouts in more European locations in
March. In some countries, the system replaces the previous-generation
Dexcom One sensor, which originally launched in the UK in 2022.
Teri Lawver, Dexcom EVP and CCO, previously said: "Dexcom ONE+
incorporates our best-in-class technology and a range of features that we
know will be well-received by the diabetes community."
www.dexcom.com/en
Abbott FDA
OK for OTC
sensor
Abbott has received clearance from
the Food and Drug Administration
in the USA for an over-the-counter
(OTC) glucose monitor. The device,
called Lingo, first debuted in the UK
last year as a sensor for people who
do not have diabetes to track glucose
spikes. Abbott now hopes to bring
it to the US and, with this recent
FDA clearance, Abbott will compete
with Dexcom for a new category of
over-the-counter glucose monitors.
A notable aspect of the clearance
is that companies must meet the
requirements of an integrated CGM
for their device to be sold over the
counter, meaning that the sensor
must provide readings that are
accurate enough to be used for
automated insulin delivery.
Cutting gout
risk
Recent research has found that
metformin use lowers the risk of
gout by 32% in individuals with
prediabetes. Individuals with
prediabetes are not only at an
elevated risk for diabetes but also
face an increased risk of developing
gout. This study assessed the goutlowering
properties of metformin in
25,064 individuals with prediabetes.
Patients who were initiated on
metformin within 18 months after
the diagnosis of prediabetes were
compared with those who did not
use metformin or other antidiabetic
medications. Those patients using
metformin were found to have 2.4
fewer cases of gout per 1000 personyears
and a 32% reduced relative risk
for incident gout. Metformin use was
also associated with a reduction in
HbA1c levels and body mass index.
Dexcom ONE+ Family with Watch